First fully integrated spatial multiomic assay from 10x Genomics (TXG) brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif ...
Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) ...
The partners are launching ImmuneScape, a multiomics program using spatial and single-cell sequencing to study immune drivers ...
Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with the Cancer ...
PLEASANTON, Calif., June 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K ...
Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region The Garvan Institute of Medical Research brings together ...
Hosted on MSN
TXG Q3 Deep Dive: Spatial Biology and Consumables Drive Outperformance Amid Macro Uncertainty
Biotech company 10x Genomics (NASDAQ:TXG) in Q3 CY2025, but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the midpoint) was ...
PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback